TESTOSTERONE

Lapse in Appropriations

For workplace safety and health, please call 800-321-6742; for mine safety and health, please call 800-746-1553; for Job Corps, please call 800-733-5627 and for Wage and Hour, please call 866-487-9243 (866-4-US-WAGE).  This website is currently not being updated due to the suspension of Federal government services. The last update to the site was 10/1/2025.  Updates to the site will start again when the Federal government resumes operations.

Chemical Identification
CAS #	58-22-0
Formula	C₁₉H₂₈O₂
Synonyms	andro; D4-androsten-17b-ol-3-one; (17b)-17-hydroxyandrost-4-en-3-one; Mertestate; Oreton; testolin; Testro AQ; virosterone

Physical Properties
Physical description	White or slightly cream-white crystals or crystalline powder.
Boiling point		Molecular weight	288.43
Freezing point/melting point	311°F	Vapor pressure	1.7x10-8 mmHg (est)
Flash point		Vapor density
Specific gravity		Ionization potential
Lower explosive limit (LEL)		Upper explosive limit (UEL)
NFPA health rating		NFPA fire rating
NFPA reactivity rating		NFPA special instruction
Vapor hazard ratio (VHR)
Historical exceedance percentage
Target organs

Monitoring Methods Used by OSHA
Analyte code (IMIS no.)	T413
Sampling group
Sampler/Sampling media	GFF Gelman Type A (37 mm) in 3-piece cassette no backup pad [SKC 225-706]
Sampling time^*	240 min
Sampling volume (TWA)^*	240 L
Sampling flow rate (TWA)^*	1 L/min
Sampling volume (STEL/Peak/C)^*
Sampling flow rate (STEL/Peak/C)^*
Analytical method instruments	HPLC
Method reference	OSHA PV2001 (partially validated)
Notes
Special requirements

^* All sampling instructions above are recommended guidelines for OSHA Compliance Safety and Health Officers (CSHOs), please see the corresponding OSHA method reference for complete details.

Bulk/Wipe Method
Wipe Sampler/Sampling media
Bulk Method

On-Site Screening Techniques
Device
Model/Type
Sampling information (see manufacturer instructions)

**Exposure Limits**
OSHA PEL 8-hour TWA (ST) STEL (C) Ceiling Peak		NIOSH REL Up to 10-hour TWA (ST) STEL (C) Ceiling		ACGIH TLV© 8-hour TWA (ST) STEL (C) Ceiling		CAL/OSHA PEL 8-hour TWA (ST) STEL (C) Ceiling Peak
PEL-TWA		REL-TWA		TLV-TWA		PEL-TWA
PEL-STEL		REL-STEL		TLV-STEL		PEL-STEL
PEL-C		REL-C		TLV-C		PEL-C
Skin notation	NA	Skin notation	NA	Skin notation	NA	Skin notation	NA
Notes: Not established		Notes: Not established		Notes: Not established		Notes: Not established
Health factors: See NIH-NLM PubChem.		IDLH
Carcinogenic classifications:		Notes:
AIHA emergency response planning guidelines - ERPG-1/ERPG-2/ERPG-3:

Additional Resources and Literature References

NOAA: CAMEO Chemicals - Not listed

NIOSH: Pocket Guide to Chemical Hazards - Not listed

Literature References

National Institute for Occupational Safety and Health: NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Publication No. 2004-165.
Abitbol, J., Abitbol, P. and Abitbol, B.: Sex hormones and the female voice. J. Voice 13(3): 424-446, 1999.
Davison, S., et al.: Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J. Clin. Pharmacol. 45(2): 177-184, 2005.
Giammanco, M., Tabacchi, G., Giammanco, S., Di Majo, D. and La Guardia, M.: Testosterone and aggressiveness. Med. Sci. Monit. 11(4): RA136-145, 2005.
Rhoden, E.L. and Morgentaler, A.: Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350(5): 482-492, 2004.
Rosenfeld, R.L.: Hirsutism and the variable response of the pilosebaceous unit to androgen. J. Investig. Dermatol. Symp. Proc. 10(3): 205-208, 2005.
Trenton, A.J. and Currier, G.W.: Behavioral manifestations of anabolic steroid use. CNS Drugs 19(7): 571-595, 2005.
Vierhapper, H., Nowotny, P. and Waldhäusl, W.: Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. J. Clin. Endocrinol. Metab. 82(5): 1492-1496, 1997.
Vierhapper, H., Maier, H., Nowotny, P. and Waldhäusl, W.: Production rates of testosterone and of dihydrotestosterone in female pattern hair loss. Metabolism 52(7): 727-729, 2003.
World Health Organization: Contraceptive efficacy of testosterone-induced azospermia and oligospermia in normal men. Fertil. Seril. 65(4): 821-829, 1996.
Zouboulis, C.C., Chen, W.C., Thornton, M.J. Qin, K. and Rosenfield, R.: Sexual hormones in human skin. Horm. Metab. Res. 39(2): 85-95, 2007.
Zumoff, B., Strain, G.W., Miller, L.K. and Rosner, W.: Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J. Clin. Endocrinol. Metab. 80(4): 1429-1430, 1995.

Last Updated Date : 01/12/2021

Lapse in Appropriations

TESTOSTERONE

Chemical Identification

Physical Properties

Monitoring Methods Used by OSHA

Bulk/Wipe Method

On-Site Screening Techniques

Exposure Limits

Additional Resources and Literature References